Cramer’s lightning round: Stick with Ford Motor over Stellantis

Cramer’s lightning round: Stick with Ford Motor over Stellantis


SoFi Technologies: “It’s just a world of hurt, but at $5 [per share], let’s just roll with it.”

Matson Inc: “I think that company ultimately is going to come under pressure. There is a lot of sense that maybe these shipping companies make a little too much money.”

Stellantis: “Like Stellantis, but let’s stick with Ford. All we need is Ford. Under $15, that’s terrific.”

Disclosure: Cramer’s Charitable Trust owns shares of Ford Motor.

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

The price of menstrual products is skyrocketing from inflation, tariffs
Business

The price of menstrual products is skyrocketing from inflation, tariffs

Always products are displayed on a shelf in a supermarket in Sarajevo, Bosnia and Herzegovina October 29, 2024.  Dado Ruvic | Reuters Rising inflation and ever-changing tariff policies have led to higher prices across store shelves over the past few years, squeezing consumers’ budgets. An often overlooked example: menstrual products. The average price of menstrual […]

Read More
Nissan’s new hybrid is a U.S.-first that mixes EV driving with a gas engine
Business

Nissan’s new hybrid is a U.S.-first that mixes EV driving with a gas engine

Nissan’s logo is illuminated on a prototype of its new all-electric Ariya crossover. Nissan’s Z Proto performance car is reflected in the vehicle’s grille, while a redesigned Nissan Pathfinder SUV sits in the background. Michael Wayland / CNBC Nissan Motor plans to introduce a new type of hybrid to the U.S. market that drives like […]

Read More
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
Business

GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

A mini burger, mini fries and mini beer, Clinton Hall’s “Teeny Weeny Mini Meal”, is pictured next to a regular-sized combo on Dec. 8, 2025 in New York City. Approximately one in eight American adults are currently taking drugs from the class of GLP-1 agonists that are now popular for weight loss, according to a […]

Read More